|Day Low/High||1.70 / 1.82|
|52 Wk Low/High||1.42 / 8.12|
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Encouraging phase 2a data suggest that aerosolized KL4 surfactant delivered to premature infants with RDS may decrease nCPAP failure and the need for intubation
Conference Call Scheduled for Thursday, November 12, 2015 at 8:00 a.m. Eastern Time
Top-line Results Expected to be Released in Mid-November
Building on results of the recently concluded phase 2a clinical trial, this phase will assess higher and repeat doses of aerosolized KL4 surfactant
Encouraging safety and physiological data suggest that aerosolized KL4 surfactant can be delivered to the lung of premature infants with respiratory distress syndrome
Conference Call Scheduled for Thursday, May 14, 2015 at 8:00 a.m. Eastern Time
-- Company Voluntarily Ceases Commercialization of SURFAXIN® --
These stocks are poised to break out and trade higher from current levels.
- Companies will Co-Invest to Advance Aerosolization Technology to a Phase 3 / Commercial-Ready Device -
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.